TYPE 2 ASTHMA
Modify | GSK 222926
Sponsor: GlaxoSmithKline (GSK)
A Phase 3b/4 randomized, double-blind, placebo-controlled, multicentre study evaluating the impact of early intervention with depemokimab on exacerbation rate, clinical remission, lung function decline, and safety in adults and adolescents with at risk Type 2 Asthma, conducted up to 156 weeks.
Interested in Learning More About Asthma Trials?
Submit your information and our team will follow up within 24–48 hours.
What Can I Expect if I Enroll?
If you are interested in learning more or enrolling, our staff will contact you within a few days.
There is no obligation, and your information will be kept confidential. Our staff will:
- Screen interested participants for eligibility in active clinical trials
- Determine whether you may qualify for participation
- Explain study details, including protocol, duration, and compensation (varies by study)
- Provide clear guidance on the study process from start to finish and answer any questions
- Communicate with your established physician, as appropriate, regarding your participation
- Patient enrollment and participation are voluntary and may be discontinued at any time
Patients enrolled in our clinical trials remain under the care of their established physician for routine healthcare.
Simply provide your contact information, and our staff will guide you through the next steps.